Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

TGFβ1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation

Abstract

Transforming growth factor beta (TGFβ) is a tumor suppressor acting as inhibitor of cell cycle progression of epithelial cells. We show that treatment of the pancreatic carcinoma cell lines PANC-1 and BxPC-3 with TGFβ1 inhibits both growth factor-induced activation of the extracellular signal-regulated kinase 2 (ERK2) and translocation of the kinase to the nucleus. TGFβ1 causes a concentration-dependent reduction of cell proliferation in both cell lines. By measuring ERK activation, we can show that TGFβ1 is able to repress ERK activation induced by mitogenic stimuli such as EGF. This inhibitory effect of TGFβ1 is not mediated by suppression of Ras or c-Raf-1 activation, but mediated by TGFβ1-induced activation of a serine-threonine phosphatase, as demonstrated by inhibition of phosphatases by treatment with okadaic acid. Results obtained in the Smad4-deficient pancreatic carcinoma cell line BxPC-3, demonstrate that TGFβ1-induced growth inhibition is mediated by a Smad4-independent prevention of ERK2 activation. In contrast to the effects of TGFβ1 on epithelial cells, mesenchymal NIH3T3 fibroblasts exhibit elevated ERK2 activation and increased cell proliferation in response to TGFβ1 treatment. Smad4-independent phosphatase-mediated inhibition of mitogen-activated ERK2 represents a novel effector pathway contributing to suppression of epithelial pancreatic carcinoma cell proliferation by TGFβ1, in addition to the well-known Smad-induced tumor suppressor activity of TGFβ.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Alessi DR, Gomez N, Moorhead G, Lewis T, Keyse SM and Cohen P. . 1995 Curr. Biol. 5: 283–295.

  • Attisano L, Carcamo J, Ventura F, Weis FM, Massagué J and Wrana JL. . 1993 Cell 75: 671–680.

  • Attisano L and Wrana JL. . 1998 Curr. Opin. Cell Biol. 10: 188–194.

  • Axmann A, Seidel D, Reimann T, Hempel U and Wenzel KW. . 1998 Biochem. Biophys. Res. Com. 249: 456–460.

  • Brondello JM, McKenzie FR, Sun H, Tonks NK and Pouysségur J. . 1995 Oncogene 10: 1895–1904.

  • Brunet A, Roux D, Lenormand P, Dowd S, Keyse S and Pouysségur J. . 1999 EMBO J. 18: 664–674.

  • Calonge MJ and Massagué J. . 1999 J. Biol. Chem. 274: 33637–33643.

  • Chen RH, Sarnecki C and Blenis J. . 1992 Mol. Cell. Biol. 12: 915–927.

  • Chen YG, Liu F and Massagué J. . 1997 EMBO J. 16: 3866–3876.

  • Dai JL, Schutte M, Bansal RK, Wilentz RE, Sugar AY and Kern SE. . 1999 Mol. Carcinog. 26: 37–43.

  • de Rooij J and Bos JL. . 1997 Oncogene 14: 623–625.

  • Dixon M, Agius L, Yeaman SJ and Day CP. . 1999 Hepatology 29: 1418–1424.

  • Dudley DT, Pang L, Decker SJ, Bridges AJ and Saltiel AR. . 1995 Proc. Natl. Acad. Sci. USA 92: 7686–7689.

  • Ebner R, Chen RH, Lawler S, Zioncheck T and Derynck R. . 1993 Science 262: 900–902.

  • Ewen ME, Sluss HK, Whitehouse LL and Livingston DM. . 1993 Cell 74: 1009–1020.

  • Franzen P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH and Miyazono K. . 1993 Cell 75: 681–692.

  • Freeman JW, Mattingly CA and Strodel WE. . 1995 J. Cell. Physiol. 165: 155–163.

  • Gardner AM, Vaillancourt RR and Johnson GL. . 1993 J. Biol. Chem. 268: 17896–17901.

  • Giehl K, Skripczynski B, Mansard A, Menke A and Gierschik P. . 2000 Oncogene 19: 2930–2942.

  • Griswold-Prenner I, Kamibayashi C, Maruoka EM, Mumby MC and Derynck R. . 1998 Mol. Cell. Biol. 18: 6595–6604.

  • Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE. . 1996 Science 271: 350–353.

  • Hartsough MT and Mulder KM. . 1995 J. Biol. Chem. 270: 7117–7124.

  • Heldin CH, Miyazono K and ten Dijke P. . 1997 Nature 390: 465–471.

  • Heldin CH and Ostman A. . 1996 Cytokine Growth Factor. Rev. 7: 3–10.

  • Herrmann C, Martin GA and Wittinghofer A. . 1995 J. Biol. Chem. 270: 2901–2905.

  • Hocevar BA, Brown TL and Howe PH. . 1999 EMBO J. 18: 1345–1356.

  • Kawabata M, Imamura T, Miyazono K, Engel ME and Moses HL. . 1995 J. Biol. Chem. 270: 29628–29631.

  • Ko TC, Yu W, Sakai T, Sheng H, Shao J, Beauchamp RD and Thompson EA. . 1998 Oncogene 16: 3445–3454.

  • Kretzschmar M, Doody J and Massagué J. . 1997 Nature 389: 618–622.

  • Kretzschmar M, Doody J, Timokhina I and Massagué J. . 1999 Genes Dev. 13: 804–816.

  • Laemmli UK. . 1970 Nature 227: 680–685.

  • Lenormand P, Sardet C, Pages G, L'Allemain G, Brunet A and Pouysségur J. . 1993 J. Cell Biol. 122: 1079–1088.

  • Liu JH, Wei S, Burnette PK, Gamero AM, Hutton M and Djeu JY. . 1999 Oncogene 18: 269–275.

  • Massagué J. . 1990 Annu. Rev. Cell Biol. 6: 597–641.

  • Massagué J. . 1998 Annu. Rev. Biochem. 67: 753–791.

  • Menke A, Geerling I, Giehl K, Vogelmann R, Reinshagen M and Adler G. . 1999 Biochim. Biophys. Acta 1449: 178–185.

  • Menke A, Yamaguchi H, Gress TM and Alder G. . 1997 Gastroenterology 113: 295–303.

  • Mulder KM and Morris SL. . 1992 J. Biol. Chem. 267: 5029–5031.

  • Pages G, Lenormand P, Allemain G, Chambard JC, Meloche S and Pouysségur J. . 1993 Proc. Natl. Acad. Sci. USA 90: 8319–8323.

  • Piek E, Heldin CH and ten Dijke P. . 1999 FASEB J. 13: 2105–2124.

  • Polyak K. . 1996 Biochim. Biophys. Acta 1242: 185–199.

  • Reimann T, Hempel U, Krautwald S, Axmann A, Scheibe R, Seidel D and Wenzel KW. . 1997 FEBS Lett. 403: 57–60.

  • Roberts AB, Heine UI, Flanders KC and Sporn MB. . 1990 Ann. N.Y. Acad. Sci 580: 225–232.

  • Rodeck U, Nishiyama T and Mauviel A. . 1999 Cancer Res. 59: 547–550.

  • Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero Jr, RA, Meltzer PS, Hahn SA and Kern SE. . 1996 Cancer Res. 56: 2527–2530.

  • Seger R and Krebs EG. . 1995 FASEB J. 9: 726–735.

  • Sporn MB and Roberts AB. . 1992 J. Cell Biol. 119: 1017–1021.

  • Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, de Villalonga P, Agell N, Lluis F, Bachs O and Capella G. . 1998 Oncogene 17: 1969–1978.

  • Wang T, Danielson PD and Li B. . 1996 Science 271: 1120–1122.

  • Zheng CF and Guan KL. . 1994 J. Biol. Chem. 269: 19947–19952.

Download references

Acknowledgements

The authors wish to thank A Mansard and S Bräg for excellent technical assistance. This work was supported by the SFB 518, DFG Kn200/4 and the BMBF (project 01-KJS-9605/2, IZKF Ulm).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giehl, K., Seidel, B., Gierschik, P. et al. TGFβ1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene 19, 4531–4541 (2000). https://doi.org/10.1038/sj.onc.1203806

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203806

Keywords

This article is cited by

Search

Quick links